RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties

← Diagnosis and Management Guides

Hemorrhagic Shock

Key considerations: Class III-IV shock (>30% blood volume loss), Occult hemorrhage (retroperitoneal, pelvic, thoracic), Coagulopathy of trauma

Cannot miss

  • Class III-IV shock (>30% blood volume loss)
  • Occult hemorrhage (retroperitoneal, pelvic, thoracic)
  • Coagulopathy of trauma

Likely diagnoses

  • Traumatic hemorrhage
  • GI hemorrhage
  • Ruptured AAA
  • Ectopic pregnancy rupture

Red flags

  • Shock index >=1
  • HR >120
  • SBP <90
  • Altered mental status
  • Pale/cold/clammy skin
  • No response to initial fluid bolus

Workup

  • history: Mechanism, estimated blood loss, anticoagulant use, prior surgeries; exam: Hemorrhagic shock class assessment (I-IV), FAST exam, source identification; labs: CBC, coags, type and crossmatch, lactate, ABG, TEG/ROTEM if available, fibrinogen; imaging: FAST exam, CXR, pelvic XR, CT if hemodynamically stable; bedside: Shock index, FAST, continuous vitals monitoring

Management

  • immediate: Hemorrhage control first — direct pressure, tourniquet, pelvic binder, chest tube; 1:1:1 blood product resuscitation (pRBC:FFP:PLT); TXA within 3 hours of injury; general: Permissive hypotension (SBP 80-90) until surgical hemorrhage control; Activate MTP for Class III-IV; Damage control surgery; Correct lethal triad (hypothermia, acidosis, coagulopathy); Calcium replacement with massive transfusion

Disposition

  • admit: OR urgently for Class III-IV, ICU for all significant hemorrhage; discharge: Class I with controlled hemorrhage after observation; consults: Trauma surgery, IR for angioembolization

Clinical pearls

  • Crystalloid resuscitation in hemorrhagic shock is harmful — dilutes clotting factors, worsens coagulopathy
  • Blood products are the resuscitation fluid of choice — not crystalloid
  • 1:1:1 ratio (PROPPR trial) demonstrated reduced 24-hour mortality compared to 2:1:1

Source and review

  • ATLS 10th Edition, PROPPR Trial 2015. Last reviewed: 2024-11-01